Back to Journals » Open Access Emergency Medicine » Volume 2

Dronedarone in the management of atrial fibrillation

Authors T S MS, Bharani K, Madhusudhana Chetty C, Gauthaman K

Published 30 March 2010 Volume 2010:2 Pages 17—23

DOI https://doi.org/10.2147/OAEM.S8988

Review by Single-blind

Peer reviewer comments 3


TS Mohamed Saleem1, K Bharani, C Madhusudhana Chetty, K Gauthaman2

1Department of Pharmacology, Annamacharya College of Pharmacy, New Boyanapalli, Rajampet, Andhrapradesh, India; 2Department of Pharmacognosy, Himalayan Pharmacy Institute, Majhitar, Sikkim, India

Abstract: Atrial fibrillation is the most common type of tachyarrhythmia caused by multiple re-entrant wave forms within the atria and bombarding the atrioventricular node several times making it beat in a rapid, disorganized fashion termed “fibrillation”. In atrial fibrillation, atria beat more than 300 times per minute. The arrhythmatous condition needs to be controlled, as humans cannot withstand this rapid and chaotic beating of the heart. New investigational drugs like Dronedarone® are being used. Dronedarone is the most recent antiarrhythmic drugs. It was approved by US-FDA on July 2nd 2009 and is available in the USA as Multaq tablets (400 mg). Dronedarone falls under the category of multiple ion channel blocker. It mainly targets the repolarization currents, making them less active and hence prolonging the action potential duration (APD). Dronedarone also exhibits antiadrenergic activity, thus reducing the pace of the pacemaker. Dronedarone has been proven to be a safer and efficacious AAD, evidenced by both animal and human studies. These studies showed that there was prolongation of the APD and absence of QT interval prolongation with long term administration of the drug. Also there was reduced thyroid hormone receptor expression. Dronedarone is significantly safer and effective in maintaining the sinus rhythm and reducing the ventricular proarrhythmias, justifying it for the long term treatment of atrial fibrillation compared to other antiarrhythmic drugs.
Keywords: dronedarone, atrial fibrillation, ion channel blocker, antiarrhythmic drugs, multaq

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]